Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Azacitidine, and Quizartinib in Newly Diagnosed AML
NCT07478991Phase 3Recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Jul 2026
- Primary completion
- Apr 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quizartinib in acute myeloid leukemia (AML) (2 arms), sponsored by Fundación PETHEMA. Primary endpoint: Overall Survival at 4 years. Started Jul 2026; status: recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07478991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478991.